PROMIS NEUROSCIENCES
PMN
 Delayed - 01/22 03:59:52 pm |
|
| 0.11CAD | --.--% |
Business Summary
| Healthcare | ||||
 | Pharmaceuticals & Medical Research | |||
| Biotechnology & Medical Research | |||
| Biotechnology & Medical Research | |||
| Bio Therapeutic Drugs | |||
ProMIS Neurosciences Inc, formerly Amorfix Life Sciences Ltd, is a Canada-based development-stage biotech company. The Company discovers and develops precision therapeutics with companion diagnostics for early detection and treatment of neurodegenerative diseases, in particular Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS). The assays are developed using its technologies, Epitope Protection and AMFIA. It is developing therapies targeting misfolded, neurotoxic forms of Amyloid beta in AD and superoxide dismutase 1 (SOD1) in ALS. The Company focuses to use its platform to discover further targets for precision medicine solutions through identification of target epitopes on other misfolded strains of Amyloid beta. The Company focuses to evaluate targets on misfolded strains of tau, another protein implicated in neurodegenerative diseases, including Alzheimer's. The Company has not generated any product revenues.
Sales per Business
| 2018 | 2019 | |||
| CAD (in Million) | % | CAD (in Million) | % | |
| Precision Medicine Solutions | 0.000 | 100% | 0.001 | 100% |
Sales per region
| 2018 | 2019 | |||
| CAD (in Million) | % | CAD (in Million) | % | |
| Canada | 0.000 | 100% | 0.001 | 100% |
Managers
| Name | Title |
| Elliot Goldstein | President, Chief Executive Officer & Director |
| Eugene Williams | Executive Chairman |
| Daniel E. Geffken | Chief Financial Officer |
| Neil R. Cashman | Director & Chief Scientific Officer |
| Johannes Minho Roth | Independent Director |
| William W. Wyman | Independent Director |
| Patrick D. Kirwin | Independent Director |
| Richard J. Gregory | Independent Director |
| Anthony J. Giovinazzo | Independent Director |
| Steven Plotkin | Chief Physics Officer |
| Shareholders |
| Name | Equities | % |
| Eugene Williams | 7,795,483 | 2.69% |
| Elliot Goldstein | 7,199,566 | 2.48% |
| Neil R. Cashman | 5,822,311 | 2.01% |
| William W. Wyman | 3,503,333 | 1.21% |
| Patrick D. Kirwin | 2,459,850 | 0.85% |
| Anthony J. Giovinazzo | 1,285,000 | 0.44% |
| Boston Private Wealth LLC | 189,710 | 0.065% |
| F.L. Putnam Investment Management Co. | 189,710 | 0.065% |
| J. M. Forbes & Co. LLP | 73,500 | 0.025% |
| David Wendell Associates, Inc. | 60,000 | 0.021% |
Company contact information
ProMIS Neurosciences, Inc.
1920 Yonge Street
Suite 200
Toronto, ON M4S 3E2
Phone : +1.416.847.6898
Fax : +1.416.847.6899
Web : http://www.promisneurosciences.com
1920 Yonge Street
Suite 200
Toronto, ON M4S 3E2
Phone : +1.416.847.6898
Fax : +1.416.847.6899
Web : http://www.promisneurosciences.com
Sector Bio Therapeutic Drugs
| 1st jan. | Capi. (M$) | ||
 | |||
| PROMIS NEUROSCIENCES, INC. | 10.00% | 25 | |
| |||
| GILEAD SCIENCES, INC. | 14.90% | 83 911 | |
| WUXI APPTEC CO., LTD. | 30.64% | 66 044 | |
| VERTEX PHARMACEUTICALS | 0.53% | 61 782 | |
| REGENERON PHARMACEUTICALS | 11.32% | 56 760 | |
| BEIGENE, LTD. | 44.94% | 34 148 | |
| GENMAB A/S | 7.31% | 28 292 | |
| BIONTECH SE | 33.02% | 26 111 | |
| ARGENX SE | 5.21% | 14 672 | |
| HUALAN BIOLOGICAL ENGINEERING INC. | 21.69% | 14 468 | |
| MYOKARDIA, INC. | 0.00% | 11 993 | |
| NEUROCRINE BIOSCIENCES, INC. | 19.98% | 10 923 | |
| MIRATI THERAPEUTICS, INC. | -2.36% | 10 783 | |
| DENALI THERAPEUTICS INC. | -5.53% | 9 489 | |
| ULTRAGENYX PHARMACEUTICAL INC. | 1.47% | 9 293 | |
| FATE THERAPEUTICS, INC. | 6.88% | 8 909 | |
| ASCENDIS PHARMA A/S | -3.67% | 8 677 | |
| ARROWHEAD PHARMACEUTICALS, INC. | 6.96% | 8 433 | |
| KODIAK SCIENCES INC. | 11.86% | 8 277 | |
| SAREPTA THERAPEUTICS, INC. | -42.38% | 7 752 | |
| ACCELERON PHARMA INC. | -2.60% | 7 508 | |
